Skip to Content

EADV 2022 update on biologics and JAK-inhibitors for the treatment of atopic dermatitis 

In line with an increased knowledge of the pathophysiological factors in atopic dermatitis, this year’s EADV 2022 presents real-world data for the Janus kinase inhibitor baricitinib and an update on the biologic drug dupilumab for moderate-to-severe AD. 

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top